Abstract:Background: The role of RASGRF2 has been verified in the development of various cancers. However, its roles in stomach adenocarcinoma (STAD) are still under investigation. Methods: RASGRF2 transcript-level data and the associated clinical information from patients with STAD were extracted from The Cancer Genome Atlas (TCGA). Diagnostic and prognostic values of RASGRF2 were analyzed using receiver-operator characteristics (ROC) analysis, correlation analysis, and survival analysis in conjunction with a prognostic model. In addition, gene expression profiles, differentially-expressed genes for co-varying expression, and a differential expressed genes (DEG) protein-protein interaction network for influential nodes were also analyzed. To identify the molecular role of RASGRF2 in STAD, gene ontology (GO) term, Kyoto Encyclopedia of Genes and Genomes (KEGG) biological pathway, and gene set enrichment analysis (GSEA)-mediated functional module enrichment analyses were conducted. The relationship between RASGRF2 and gene signature-based predicted immune cell infiltration patterns were also investigated. To validate the bioinformatic findings, RASGRF2 protein expression was investigated in vitro using western blot and immunohistochemistry. Furthermore, relationships among RASGRF2 protein expression, clinicopathologic characteristics, and patient survival were analyzed. Results: Bioinformatic analysis revealed a significantly higher RASGRF2 transcript level in STAD tissue, which was positively associated with the T stage, histological type, histological grade, and TP53 status. Moreover, the RASGRF2 transcript level indicated poor overall survival in STAD patients (hazard ratio = 1.47, P = 0.023). Multivariate Cox regression analysis showed that primary therapy outcome, age, and RASGRF2 transcript level were independent prognostic factors for survival, and the C-index of a nomogram was 0.695. Additionally, 159 genes were differentially expressed according to RASGRF2 transcript levels; 15 exhibited co-varying expression, and 13 were identified as influential nodes. The DEG-list was significantly enriched for several GO terms, biological pathways, and functional modules, including MAPK, RAS, ERK, and immunoregulatory pathways. RASGRF2 transcript levels were significantly positively correlated with infiltration levels of Tem, Macrophages, pDCs, and NK cells. Validation analysis showed similar results for the RASGRF2 protein expression level in both in vitro analyses. Conclusion: Bioinformatic predictions combined with in vitro validation suggest that RASGRF2 plays diagnostic and prognostic roles and serves as a negative protective molecular factor in STAD patients.

Clinical significance of RASAL1 expression in colorectal carcinoma

Clinical significance of expression of RASAL1 in gastric cancer

In Vivo and in Vitro Expression of the RASAL1 Gene in Human Gastric Adenocarcinoma and Its Clinicopathological Significance.

RASAL1 Influences the Proliferation and Invasion of Gastric Cancer Cells by Regulating the RAS/ERK Signaling Pathway

High Expression of Lncrna MALAT1 Suggests a Biomarker of Poor Prognosis in Colorectal Cancer.

Expression and Biological Significance of Ras Protein Activator Like-1 Gene in Gastric Cancer Cell Lines

RASAL1 Expression and Ras Activity with Gastrointestinal Tumors: a Review

Loss of RASSF1A Expression in Colorectal Cancer and Its Association with K-ras Status

RASGRP2 is a potential immune-related biomarker and regulates mitochondrial-dependent apoptosis in lung adenocarcinoma

Hypermethylation and clinicopathological significance of RASAL1 gene in gastric cancer.

Clinical Study of Expression Levels of RASGRF1 in Colorectal Cancer Tissues

[Expression of RASAL2 in hepatocellular carcinoma and the clinical significance].

RASAL1 attenuates gastric carcinogenesis in nude mice by blocking RAS/ERK signaling.

Enforced Expression of RASAL1 Suppresses Cell Proliferation and the Transformation Ability of Gastric Cancer Cells.

Expression and clinical significance of RCC1 in rectal cancer tissues

Downregulation of Rasal2 Promotes the Proliferation, Epithelial-Mesenchymal Transition and Metastasis of Colorectal Cancer Cells

High Expression of ERK-related RASGRF2 Predicts Poor Prognosis in Patients with Stomach Adenocarcinoma and Correlates with M2 Macrophage

Expression of RhoA and RhoC in Colorectal Carcinoma and Its Relations with Clinicopathological Parameters.

Decreased expression of RASSF10 correlates with poor prognosis in patients with colorectal cancer.

High Expression of Ras-related Protein 1A Promotes an Aggressive Phenotype in Colorectal Cancer Via PTEN/FOXO3/CCND1 Pathway.

Low Expression of RASSF10 is Associated with Poor Survival in Patients with Colorectal Cancer.